Metacam Oral Suspension | 
Metacam treats arthritis and other causes of pain and inflammation, especially those affecting the musculo-skeletal system. It can also be used to relieve pain and reduce inflammation after surgical operations, or to aid treatment in certain types of infection. Metacam belongs to the group of drugs known as non-steroidal anti-inflammatory drugs and is one of the safest available for use in dogs, cats and horses. Metacam is supplied as a pleasantly flavoured liquid to be given by mouth or with food. If the dose is given directly into the mouth, this is best done after a meal. Metacam side effects are reduced through its ability to target the sites of inflammation while having much less effect than many other medications on the gut lining and kidneys.
Metacam is not advised for animals which are dehydrated, and care is
needed where conditions affecting the kidneys or gut lining are
suspected. | | | | Metacam Oral Suspension | Cat 3ml Bottle
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£6.02
(inc. VAT) | | Cat 15ml bottle
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£8.92
(inc. VAT) | | Dog 10ml Bottle
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£3.07
(inc. VAT) | | Dog 32ml Bottle
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£7.22
(inc. VAT) | | Dog 100ml Bottle
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£16.13
(inc. VAT) | | Dog 180ml Bottle
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£19.30
(inc. VAT) | | Horse 100ml Bottle
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£40.14
(inc. VAT) | | Horse 250ml Bottle
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£76.55
(inc. VAT) | | |
| Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
One ml of Metacam Oral Suspension for Cats contains 0.5 mg meloxicam as active ingredient (equivalent to 0.017 mg per drop) and 1.5 mg sodium benzoate (equivalent to 0.05 mg per drop).
Uses
Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in cats. For alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. For alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats.
Dosage and administration Post-operative pain and inflammation following surgical procedures:
After initial treatment with Metacam 2 mg/ml solution for injection for cats, continue treatment 24 hours later with Metacam 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days.
Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.
A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.
Route and method of administration
Dosing procedure using the drop dispenser of the bottle:
Dose of 0.1 mg meloxicam/kg body weight:6 drops /kg body weight
Dose of 0.05 mg meloxicam/kg body weight:3 drops /kg body weight
Dosing procedure using the measuring syringe:
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to dose of 0.05 mg meloxicam/kg body weight. Thus for initiation of the treatment of chronic musculo-skeletal disorders on the first day, twice the maintenance volume will be required.
Shake well before use. To be administered orally either mixed with food or directly into the mouth.
The suspension can be given using the drop dispenser of the bottle for cats of any body weight. Alternatively and for cats with a body weight of at least 2 kg, the measuring syringe provided in the package can be used.
Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded.
Avoid introduction of contamination during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastro-intestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in cats less than 6 weeks of age.
Typical adverse drug reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Post-operative pain and inflammation following surgical procedures:
In case additional pain relief is required, multimodal pain therapy should be considered.
Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Other NSAIDs, diuretics, anticoagulant, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels.
In case of overdose, adverse reactions, as listed in section 4.6, are expected to be more severe and more frequent. In case of overdose symptomatic treatment should be initiated.
User precautions
People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Disposal Advice
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only.
Keep out of reach of children.
Pharmaceutical precautions
Shelf-life after first opening the immediate packaging:
3 ml bottle: 14 days
15 ml bottle: 6 months
Legal category
POM-V
Packaging Quantities
Polyethylene bottles containing 3 ml or 15 ml with a polyethylene dropper, a tamper-proof child resistant closure and a polypropylene measuring syringe. The 1 ml measuring syringe has a kg-bodyweight scale for cats (2 to 10 kg) and has a pictogram showing a cat.
Further information Pharmacodynamic properties
Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Pharmacokinetic properties
Absorption
If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Five major metabolites have been identified. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. As for other species investigated, the main pathway of meloxicam biotransformation in cat is oxidation and there are no pharmacologically active metabolites.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21% of the recovered dose is eliminated in urine (2% as unchanged meloxicam, 19% as metabolites) and 79% in the faeces (49% as unchanged meloxicam, 30% as metabolites).
Marketing authorisation number
EU/2/97/004/034 – 3 ml.
EU/2/97/004/026 – 15 ml.
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim am Rhein
Germany
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
One ml of Metacam Oral Suspension for Cats contains 0.5 mg meloxicam as active ingredient (equivalent to 0.017 mg per drop) and 1.5 mg sodium benzoate (equivalent to 0.05 mg per drop).
Uses
Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in cats. For alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. For alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats.
Dosage and administration Post-operative pain and inflammation following surgical procedures:
After initial treatment with Metacam 2 mg/ml solution for injection for cats, continue treatment 24 hours later with Metacam 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days.
Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.
A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.
Route and method of administration
Dosing procedure using the drop dispenser of the bottle:
Dose of 0.1 mg meloxicam/kg body weight:6 drops /kg body weight
Dose of 0.05 mg meloxicam/kg body weight:3 drops /kg body weight
Dosing procedure using the measuring syringe:
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to dose of 0.05 mg meloxicam/kg body weight. Thus for initiation of the treatment of chronic musculo-skeletal disorders on the first day, twice the maintenance volume will be required.
Shake well before use. To be administered orally either mixed with food or directly into the mouth.
The suspension can be given using the drop dispenser of the bottle for cats of any body weight. Alternatively and for cats with a body weight of at least 2 kg, the measuring syringe provided in the package can be used.
Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded.
Avoid introduction of contamination during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastro-intestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in cats less than 6 weeks of age.
Typical adverse drug reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Post-operative pain and inflammation following surgical procedures:
In case additional pain relief is required, multimodal pain therapy should be considered.
Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Other NSAIDs, diuretics, anticoagulant, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels.
In case of overdose, adverse reactions, as listed in section 4.6, are expected to be more severe and more frequent. In case of overdose symptomatic treatment should be initiated.
User precautions
People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Disposal Advice
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only.
Keep out of reach of children.
Pharmaceutical precautions
Shelf-life after first opening the immediate packaging:
3 ml bottle: 14 days
15 ml bottle: 6 months
Legal category
POM-V
Packaging Quantities
Polyethylene bottles containing 3 ml or 15 ml with a polyethylene dropper, a tamper-proof child resistant closure and a polypropylene measuring syringe. The 1 ml measuring syringe has a kg-bodyweight scale for cats (2 to 10 kg) and has a pictogram showing a cat.
Further information Pharmacodynamic properties
Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Pharmacokinetic properties
Absorption
If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Five major metabolites have been identified. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. As for other species investigated, the main pathway of meloxicam biotransformation in cat is oxidation and there are no pharmacologically active metabolites.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21% of the recovered dose is eliminated in urine (2% as unchanged meloxicam, 19% as metabolites) and 79% in the faeces (49% as unchanged meloxicam, 30% as metabolites).
Marketing authorisation number
EU/2/97/004/034 – 3 ml.
EU/2/97/004/026 – 15 ml.
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim am Rhein
Germany
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
One ml of Metacam Oral Suspension for Dogs contains 1.5 mg meloxicam as active ingredient (equivalent to 0.05 mg per drop) and 1.5 mg sodium benzoate (equivalent to 0.05 mg per drop).
Uses
Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs.
For alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Dosage and administration
Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/ kg bodyweight.
For longer term treatment, once clinical response has been observed (after > 4 days), the dose of Metacam can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Particular care should be taken with regard to the accuracy of dosing.
Shake well before use. To be administered orally either mixed with food or directly into the mouth. The suspension can be given using either the drop dispenser of the bottle (for very small breeds) or the Metacam measuring syringe provided in the package.
Dosing procedure using the drop dispenser of the bottle.
Initial dose : 4 drops/kg bodyweight.
Maintenance dose : 2 drops/kg bodyweight.
Dosing procedure using the measuring syringe.
The syringe fits onto the drop dispenser of the bottle and has a kg-bodyweight scale which corresponds to the maintenance dose (ie. 0.1 mg meloxicam/kg bodyweight). Thus for the first day of treatment, twice the maintenance volume will be required.
Alternatively, treatment may be initiated with Metacam 5 mg/ml solution for injection.
A clinical response is usually seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
Avoid the introduction of contamination during use
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastro-intestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivy to the active substance or to any of the excipients.
Do not use in dogs less than 6 weeks of age.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood , apathy and renal failure have occasionally been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Metacam 0.5 mg/ml Oral Suspension for Cats should be used.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
In case of overdose, symptomatic treatment should be initiated.
User precautions
Individuals sensitive to NSAIDs should avoid contact with the product. In case of accidental self-administration, seek medical advice immediately and show the package insert or label to the Doctor.
Any unused product or waste materials should be disposed or in accordance with national requirements for pharmaceutical products.
For animal treatment only.
Keep out of reach of children.
Pharmaceutical precautions
After first opening the bottle, use contents within 6 months and then discard any remaining unused product.
Legal category
POM-V
Packaging Quantities
Polyethylene bottles containing 10 ml, 32 ml, 100 ml or 180 ml with a polyethylene dropper, a tamper-proof child resistant closure and a polypropylene measuring syringe.
Further information
Pharmacodynamic properties
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Pharmacokinetic particulars
Absorption
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Marketing authorisation number
EU/2/97/004/003 : 10 ml.
EU/2/97/004/004 : 32 ml.
EU/2/97/004/005 : 100 ml.
EU/2/97/004/029 : 180 ml.
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim am Rhein
Germany
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
One ml of Metacam Oral Suspension for Dogs contains 1.5 mg meloxicam as active ingredient (equivalent to 0.05 mg per drop) and 1.5 mg sodium benzoate (equivalent to 0.05 mg per drop).
Uses
Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs.
For alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Dosage and administration
Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/ kg bodyweight.
For longer term treatment, once clinical response has been observed (after > 4 days), the dose of Metacam can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Particular care should be taken with regard to the accuracy of dosing.
Shake well before use. To be administered orally either mixed with food or directly into the mouth. The suspension can be given using either the drop dispenser of the bottle (for very small breeds) or the Metacam measuring syringe provided in the package.
Dosing procedure using the drop dispenser of the bottle.
Initial dose : 4 drops/kg bodyweight.
Maintenance dose : 2 drops/kg bodyweight.
Dosing procedure using the measuring syringe.
The syringe fits onto the drop dispenser of the bottle and has a kg-bodyweight scale which corresponds to the maintenance dose (ie. 0.1 mg meloxicam/kg bodyweight). Thus for the first day of treatment, twice the maintenance volume will be required.
Alternatively, treatment may be initiated with Metacam 5 mg/ml solution for injection.
A clinical response is usually seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
Avoid the introduction of contamination during use
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastro-intestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivy to the active substance or to any of the excipients.
Do not use in dogs less than 6 weeks of age.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood , apathy and renal failure have occasionally been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Metacam 0.5 mg/ml Oral Suspension for Cats should be used.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
In case of overdose, symptomatic treatment should be initiated.
User precautions
Individuals sensitive to NSAIDs should avoid contact with the product. In case of accidental self-administration, seek medical advice immediately and show the package insert or label to the Doctor.
Any unused product or waste materials should be disposed or in accordance with national requirements for pharmaceutical products.
For animal treatment only.
Keep out of reach of children.
Pharmaceutical precautions
After first opening the bottle, use contents within 6 months and then discard any remaining unused product.
Legal category
POM-V
Packaging Quantities
Polyethylene bottles containing 10 ml, 32 ml, 100 ml or 180 ml with a polyethylene dropper, a tamper-proof child resistant closure and a polypropylene measuring syringe.
Further information
Pharmacodynamic properties
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Pharmacokinetic particulars
Absorption
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Marketing authorisation number
EU/2/97/004/003 : 10 ml.
EU/2/97/004/004 : 32 ml.
EU/2/97/004/005 : 100 ml.
EU/2/97/004/029 : 180 ml.
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim am Rhein
Germany
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
One ml of Metacam Oral Suspension for Dogs contains 1.5 mg meloxicam as active ingredient (equivalent to 0.05 mg per drop) and 1.5 mg sodium benzoate (equivalent to 0.05 mg per drop).
Uses
Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs.
For alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Dosage and administration
Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/ kg bodyweight.
For longer term treatment, once clinical response has been observed (after > 4 days), the dose of Metacam can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Particular care should be taken with regard to the accuracy of dosing.
Shake well before use. To be administered orally either mixed with food or directly into the mouth. The suspension can be given using either the drop dispenser of the bottle (for very small breeds) or the Metacam measuring syringe provided in the package.
Dosing procedure using the drop dispenser of the bottle.
Initial dose : 4 drops/kg bodyweight.
Maintenance dose : 2 drops/kg bodyweight.
Dosing procedure using the measuring syringe.
The syringe fits onto the drop dispenser of the bottle and has a kg-bodyweight scale which corresponds to the maintenance dose (ie. 0.1 mg meloxicam/kg bodyweight). Thus for the first day of treatment, twice the maintenance volume will be required.
Alternatively, treatment may be initiated with Metacam 5 mg/ml solution for injection.
A clinical response is usually seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
Avoid the introduction of contamination during use
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastro-intestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivy to the active substance or to any of the excipients.
Do not use in dogs less than 6 weeks of age.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood , apathy and renal failure have occasionally been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Metacam 0.5 mg/ml Oral Suspension for Cats should be used.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
In case of overdose, symptomatic treatment should be initiated.
User precautions
Individuals sensitive to NSAIDs should avoid contact with the product. In case of accidental self-administration, seek medical advice immediately and show the package insert or label to the Doctor.
Any unused product or waste materials should be disposed or in accordance with national requirements for pharmaceutical products.
For animal treatment only.
Keep out of reach of children.
Pharmaceutical precautions
After first opening the bottle, use contents within 6 months and then discard any remaining unused product.
Legal category
POM-V
Packaging Quantities
Polyethylene bottles containing 10 ml, 32 ml, 100 ml or 180 ml with a polyethylene dropper, a tamper-proof child resistant closure and a polypropylene measuring syringe.
Further information
Pharmacodynamic properties
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Pharmacokinetic particulars
Absorption
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Marketing authorisation number
EU/2/97/004/003 : 10 ml.
EU/2/97/004/004 : 32 ml.
EU/2/97/004/005 : 100 ml.
EU/2/97/004/029 : 180 ml.
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim am Rhein
Germany
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
One ml of Metacam Oral Suspension for Dogs contains 1.5 mg meloxicam as active ingredient (equivalent to 0.05 mg per drop) and 1.5 mg sodium benzoate (equivalent to 0.05 mg per drop).
Uses
Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs.
For alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Dosage and administration
Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/ kg bodyweight.
For longer term treatment, once clinical response has been observed (after > 4 days), the dose of Metacam can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Particular care should be taken with regard to the accuracy of dosing.
Shake well before use. To be administered orally either mixed with food or directly into the mouth. The suspension can be given using either the drop dispenser of the bottle (for very small breeds) or the Metacam measuring syringe provided in the package.
Dosing procedure using the drop dispenser of the bottle.
Initial dose : 4 drops/kg bodyweight.
Maintenance dose : 2 drops/kg bodyweight.
Dosing procedure using the measuring syringe.
The syringe fits onto the drop dispenser of the bottle and has a kg-bodyweight scale which corresponds to the maintenance dose (ie. 0.1 mg meloxicam/kg bodyweight). Thus for the first day of treatment, twice the maintenance volume will be required.
Alternatively, treatment may be initiated with Metacam 5 mg/ml solution for injection.
A clinical response is usually seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
Avoid the introduction of contamination during use
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastro-intestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivy to the active substance or to any of the excipients.
Do not use in dogs less than 6 weeks of age.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood , apathy and renal failure have occasionally been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Metacam 0.5 mg/ml Oral Suspension for Cats should be used.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
In case of overdose, symptomatic treatment should be initiated.
User precautions
Individuals sensitive to NSAIDs should avoid contact with the product. In case of accidental self-administration, seek medical advice immediately and show the package insert or label to the Doctor.
Any unused product or waste materials should be disposed or in accordance with national requirements for pharmaceutical products.
For animal treatment only.
Keep out of reach of children.
Pharmaceutical precautions
After first opening the bottle, use contents within 6 months and then discard any remaining unused product.
Legal category
POM-V
Packaging Quantities
Polyethylene bottles containing 10 ml, 32 ml, 100 ml or 180 ml with a polyethylene dropper, a tamper-proof child resistant closure and a polypropylene measuring syringe.
Further information
Pharmacodynamic properties
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Pharmacokinetic particulars
Absorption
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Marketing authorisation number
EU/2/97/004/003 : 10 ml.
EU/2/97/004/004 : 32 ml.
EU/2/97/004/005 : 100 ml.
EU/2/97/004/029 : 180 ml.
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim am Rhein
Germany
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
One ml of Metacam 15 mg/ml oral suspension contains Meloxicam 15 mg as active substance and Sodium benzoate 1.5 mg
Uses
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
Dosage and administration
To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days. Where the product is mixed with food, it should be added to a small quantity of food, prior to feeding.
The suspension should be given using the Metacam measuring syringe provided in the package. The syringe fits onto the bottle and has a kg-body weight scale.
Shake well before use.
Avoid introduction of contamination during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating mares.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in horses less than 6 weeks of age.
Isolated cases of adverse reactions typically associated with NSAIDs were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Laboratory studies in cattle have not provided any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore the use in this species is not recommended during pregnancy and lactation.
Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.
In the case of overdosage symptomatic treatment should be initiated.
Withdrawal period
Meat and offal: 3 days.
Operator warnings
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Disposal Advice
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only.
Keep out of reach and sight of children.
Pharmaceutical precautions
Use within 6 months of first opening.
Do not use after the expiry date stated on the carton and on the bottle.
Legal category
POM-V
Packaging Quantities
Polyethylene bottle containing 100 ml or 250 ml with a polyethylene tip adapter, a tamper proof child resistant closure and a polypropylene measuring syringe.
Further information
Pharmacodynamic properties
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by intravenous E. coli endotoxin administration in calves and pigs.
Pharmacokinetic particulars
Absorption
When the product is used according to the recommended dosage regime the oral bioavailability is approximately 98%. Maximal plasma concentrations are obtained after approximately 2 - 3 hours. The accumulation factor of 1.08 suggests that meloxicam does not accumulate when administered daily.
Distribution
Approximately 98% of meloxicam is bound to plasma proteins. The volume of distribution is 0.12 l/kg
Metabolism
The metabolism is qualitatively similar in rats, mini-pigs, humans, cattle and pigs although quantitatively there are differences. The major metabolites found in all species were the 5-hydroxy- and 5-carboxy-metabolites and the oxalyl-metabolite. The metabolism in horses was not investigated. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a terminal half-life of 7.7 hours.
Marketing authorisation number
EU/2/97/004/009 : 100 ml.
EU/2/97/004/030 : 250 ml.
Marketing Authorisation Holder.
Boehringer Ingelheim Vetmedica GmbH.
D 55216 Ingelheim, Germany.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
One ml of Metacam 15 mg/ml oral suspension contains Meloxicam 15 mg as active substance and Sodium benzoate 1.5 mg
Uses
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
Dosage and administration
To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days. Where the product is mixed with food, it should be added to a small quantity of food, prior to feeding.
The suspension should be given using the Metacam measuring syringe provided in the package. The syringe fits onto the bottle and has a kg-body weight scale.
Shake well before use.
Avoid introduction of contamination during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating mares.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in horses less than 6 weeks of age.
Isolated cases of adverse reactions typically associated with NSAIDs were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Laboratory studies in cattle have not provided any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore the use in this species is not recommended during pregnancy and lactation.
Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.
In the case of overdosage symptomatic treatment should be initiated.
Withdrawal period
Meat and offal: 3 days.
Operator warnings
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Disposal Advice
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only.
Keep out of reach and sight of children.
Pharmaceutical precautions
Use within 6 months of first opening.
Do not use after the expiry date stated on the carton and on the bottle.
Legal category
POM-V
Packaging Quantities
Polyethylene bottle containing 100 ml or 250 ml with a polyethylene tip adapter, a tamper proof child resistant closure and a polypropylene measuring syringe.
Further information
Pharmacodynamic properties
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by intravenous E. coli endotoxin administration in calves and pigs.
Pharmacokinetic particulars
Absorption
When the product is used according to the recommended dosage regime the oral bioavailability is approximately 98%. Maximal plasma concentrations are obtained after approximately 2 - 3 hours. The accumulation factor of 1.08 suggests that meloxicam does not accumulate when administered daily.
Distribution
Approximately 98% of meloxicam is bound to plasma proteins. The volume of distribution is 0.12 l/kg
Metabolism
The metabolism is qualitatively similar in rats, mini-pigs, humans, cattle and pigs although quantitatively there are differences. The major metabolites found in all species were the 5-hydroxy- and 5-carboxy-metabolites and the oxalyl-metabolite. The metabolism in horses was not investigated. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a terminal half-life of 7.7 hours.
Marketing authorisation number
EU/2/97/004/009 : 100 ml.
EU/2/97/004/030 : 250 ml.
Marketing Authorisation Holder.
Boehringer Ingelheim Vetmedica GmbH.
D 55216 Ingelheim, Germany.
| 
